Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Xarelto® for the Prevention of Stroke and Noncentral Nervous Systemic Embolism in Non-valvular Atrial Fibrillation With REnal Impairment in Taiwanese Population.

NCT04356989 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04356989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04356989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Xarelto® for the Prevention of Stroke and Noncentral Nervous Systemic Embolism in Non-valvular Atrial Fibrillation With REnal Impairment in Taiwanese Population.
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
May 13, 2020
Completion date
January 16, 2023
Enrollment
493 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation (nvaf)